Business Context and Reporting Period
This Form 8-K is a current report filed by Astro-Med, Inc. (not Astronova, Inc.) on January 30, 2012. The report details the approval of a new compensation program for non-employee directors, effective February 1, 2012.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and director compensation arrangements.
Material Changes
The primary material change is the implementation of the Astro-Med, Inc. Non-Employee Director Annual Compensation Program. Key components include:
- Cash Retainer: An annual cash retainer paid in four equal quarterly installments, plus $500 per Board or committee meeting attended (capped at $500 per day).
- Equity Retainer: Commencing with the 2012 annual meeting, directors receive a restricted stock award valued at $20,000.
- Stock Election: Directors may elect to receive all or part of the Cash Retainer in common stock, issued quarterly based on fair market value.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. It outlines specific vesting and transfer restrictions for the equity awards:
- Vesting: The Equity Retainer vests on the earlier of 12 months after the grant date or the day prior to the next annual meeting.
- Transfer Restrictions: Vested Equity Retainer shares cannot be sold or transferred prior to the second anniversary of the vesting date. Shares received in lieu of the Cash Retainer cannot be sold prior to the first anniversary of the grant date.
- Exceptions: Restrictions are waived immediately in the event of a director's death, disability, or a Change in Control.
Investor Verification Checklist
- Verify the total number of non-employee directors to estimate the aggregate annual compensation cost.
- Review the company's 2007 Equity Incentive Plan to understand the specific definition of "Change in Control."
- Monitor future filings for the actual issuance of restricted stock and the number of shares granted based on market price.
- Confirm if any directors elected to receive their Cash Retainer in stock versus cash in subsequent quarters.